Dr Dean Craig Singleton
Dean Singleton obtained his BSc(Hons) in Biomedical Sciences at the University of Auckland and his PhD in Molecular Medicine and Pathology at the University of Auckland under the supervision of Associate Professor Adam Patterson and Professor Bill Wilson. He then completed a postdoctoral fellowship in the laboratory of Professor Adrian Harris at the Weatherall Institute of Molecular Medicine, University of Oxford, investigating transcriptional responses to tumour hypoxia. In 2014 he joined the laboratory of Dr Susanne Müller-Knapp in the Nuffield Department of Medicine, University of Oxford, developing chemical probes to target epigenetic proteins. In 2015 he was awarded the Rodney and Elaine Davies Cancer Research Fellowship to return to the University of Auckland.
Dr Singleton’s primary interest is in the development of antitumour agents that target tumour hypoxia with a focus on blocking the epigenetic reprogramming implicated in transcriptional responses to hypoxia.
Research | Current
My research aims to identify and develop new approaches to treat cancer. These projects include a combination of medicinal chemistry, functional genomics, cancer metabolism and cellular biology.
My current projects include:
- Can targeting glutamine metabolism destabilise HIF-1α in Triple receptor Negative Breast Cancer?
- Can targeting PERK (an immunosuppressive stress kinase) in immune cells restore antitumour immunity and enhance the activity of immune checkpoint therapy?
- Can whole genome CRISPR/Cas9 screens identify genes that are required for growth and survival of IDH1 mutant brain cancers?
Teaching | Current
MEDSCI 302 - Cancer Biology
MEDSCI 714 - Advanced Cancer Biology
MEDSCI 700 - Drug Discovery Biology
Selected publications and creative works (Research Outputs)
- Singleton, D. C., Dechaume, A.-L., Murray, P. M., Katt, W. P., Baguley, B. C., & Leung, E. Y. (2020). Pyruvate anaplerosis is a mechanism of resistance to pharmacological glutaminase inhibition in triple-receptor negative breast cancer. BMC cancer, 20 (1)10.1186/s12885-020-06885-3
Other University of Auckland co-authors: Euphemia Leung
- Hearn, J. I., Green, T. N., Chopra, M., Nursalim, Y. N. S., Ladvanszky, L., Knowlton, N., ... Bohlander, S. K. (2020). N-Methyl-D-Aspartate Receptor Hypofunction in Meg-01 Cells Reveals a Role for Intracellular Calcium Homeostasis in Balancing Megakaryocytic-Erythroid Differentiation. Thrombosis and haemostasis, 120 (4), 671-686. 10.1055/s-0040-1708483
Other University of Auckland co-authors: Cherie Blenkiron, James Hearn, Taryn Green, Nicholas Knowlton, Stefan Bohlander, Raewyn Poulsen, Maggie Kalev, Yohanes Nursalim
- Hearn, J. I., Green, T. N., Chopra, M., Nursalim, Y. N. S., Ladvanszky, L., Knowlton, N., ... Bohlander, S. K. (2020). N -Methyl-D-Aspartate Receptor Hypofunction in Meg-01 Cells Reveals a Role for Intracellular Calcium Homeostasis in Balancing Megakaryocytic-Erythroid Differentiation. THROMBOSIS AND HAEMOSTASIS, 120 (4), 671-686. 10.1055/s-0040-1708483.
Other University of Auckland co-authors: Raewyn Poulsen, James Hearn, Nicholas Knowlton, Cherie Blenkiron, Maggie Kalev, Stefan Bohlander, Yohanes Nursalim
- Liew, L. P., Singleton, D. C., Wong, W. W., Cheng, G. J., Jamieson, S. M. F., & Hay, M. P. (2019). Hypoxia‐Activated Prodrugs of PERK Inhibitors. Chemistry - An Asian Journal, 14 (8), 1238-1248. 10.1002/asia.201801826
Other University of Auckland co-authors: Lydia Liew, Way Wong, Stephen Jamieson, Michael Hay
- Singleton, D. C., & Harris, A. L. (2019). ATF4, Hypoxia and Treatment Resistance in Cancer. Cancer Drug Discovery and Development (pp. 75-108). 10.1007/978-3-030-05067-2_4
- Leung, E. Y., Askarian-Amiri, M. E., Singleton, D. C., Ferraro-Peyret, C., Joseph, W. R., Finlay, G. J., ... Marshall, E. (2018). Derivation of Breast Cancer Cell Lines Under Physiological (5%) Oxygen Concentrations. FRONTIERS IN ONCOLOGY, 810.3389/fonc.2018.00425
Other University of Auckland co-authors: Euphemia Leung, Graeme Finlay, Stefan Bohlander, Purvi Kakadiya
- Liew, L. P., Wong, W. W., Singleton, D. C., Jamieson, S. M. F., Flanagan, J. U., Koumenis, C., & Hay, M. P. (2017). The development of hypoxia-selective prodrugs of the PERK inhibitor. Paper presented at 15th International Tumor Microenvironment Workshop, Miami, Florida. 27 April - 29 April 2017.
Other University of Auckland co-authors: Lydia Liew, Way Wong, Stephen Jamieson, Jack Flanagan, Michael Hay
- McIntyre, A., Hulikova, A., Ledaki, I., Snell, C., Singleton, D., Steers, G., ... Wigfield, S. (2016). Disrupting hypoxia-induced bicarbonate transport acidifies tumor cells and suppresses tumor growth. Cancer Research, 76 (13), 1-12. 10.1158/0008-5472.CAN-15-1862